Selina M. Luger

Selina M. Luger

Auto-generated profile, based on publicly available information

Selina M. Luger

Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2019 in Blood
Verified
Journal Article
Open access
PDF file
WSWendy Stock
Wendy Stock
SLSelina M. Luger
Selina M. Luger
AAAnjali S. Advani
Anjali S. Advani
JYJun Yin
Jun Yin
RHRichard C. Harvey
Richard C. Harvey
RLRichard A. Larson
Richard A. Larson
Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's Oncology Group study AALL0232. From 2007 to 2012, 318 patients were enrolled; 295 were eligible and evaluable for response. Median age was 24 years (range, 17-39 years). Use of the pediatric regimen was safe; overall treatment-related mortality was 3%, and there were only 2 postremission deaths. Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8 to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%). Median overall survival (OS) was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature. Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00558519.

4 March 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
MSMaximilian Stahl
Maximilian Stahl
RSRory Shallis
Rory Shallis
WWWei Wei
Wei Wei
PMPau Montesinos
Pau Montesinos
ELEtienne Lengline
Etienne Lengline
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan

18 March 2019 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
CMChristine M. McMahon
Christine M. McMahon
SLSelina M. Luger
Selina M. Luger

1 January 2006 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
AMAnthony R. Mato
Anthony R. Mato
BRBrett E. Riccio
Brett E. Riccio
LQLi Qin
Li Qin
DHDaniel F. Heitjan
Daniel F. Heitjan
MCMartin Carroll
Martin Carroll
SLSelina M. Luger
Selina M. Luger
Tumor lysis syndrome (TLS) is defined by metabolic derangements occurring in the setting of rapid tumor destruction. In acute myelogenous leukemia (AML), TLS frequency, risk stratification, monitoring, and management strategies are based largely on case series and data from other malignancies. A single-center, retrospective cohort study was conducted to estimate TLS incidence and identify TLS predictive factors in a patient population undergoing myeloid leukemia induction chemotherapy. This study included 194 patients, aged 18–86 years, with AML or advanced myelodysplastic syndrome undergoing primary myeloid leukemia induction chemotherapy. Nineteen patients (9.8%) developed TLS. In univariate analysis, elevated pre-chemotherapy values for uric acid (P < 0.0001), creatinine (P = 0.0025), lactate dehydrogenase (LDH) (P = 0.0001), white blood cell (P = 0.0058), gender (P = 0.0064) and chronic myelomonocytic leukemia history (P = 0.0292) were significant predictors. In multivariate analysis, LDH (P = 0.0042), uric acid (P < 0.0001) and gender (P = 0.0073) remained significant TLS predictors. A predictive model was then designed using a scoring system based on these factors. This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population.


21 January 2017 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
PSPamela J. Sung
Pamela J. Sung
SLSelina M. Luger
Selina M. Luger